Use Intermountain Connect Care®
Get care for low-level urgent conditions through a video chat with a provider, 24/7, on your computer or mobile device.
Learn More.
Learn More.
Salt Lake City – Intermountain Precision Genomics Medical Director Lincoln Nadauld, MD, will present his recently published abstract at the American Association for Cancer Research (AARC) conference in Salt Lake City, Utah on June 16, 2015. The goal of the conference is to highlight technology and advances in cancer research that, together, are enabling treatments that are precisely targeted to the unique molecular and genetic characteristics of an individual’s cancer.
The invitation to present includes topics on integrating clinical genomics and cancer therapy in conjunction with Dr. Nadauld’s findings on outcomes in advanced cancer patients. Dr. Nadauld’s research also appears in the conference publication for the American Society of Clinical Oncologists:
- Precision medicine to improve survival without increasing costs in advanced cancer patients
- Implementation of a precision cancer program in an integrated health care system
“One of the most important reasons for publication of our work is to establish best practices and best standards for personalized medicine,” said Gary Stone, operations officer for Intermountain Precision Genomics. “It’s also key for Intermountain Healthcare to keep its status of a rising thought leader in precision medicine. We can accomplish that through peer-reviewed publications.”
Stone explained that because Dr. Nadauld’s is a physician and scientist, he is able to bridge the gap between new medical scientific discoveries and actual clinical utility. “Lincoln is brilliant. One of the smartest people I know.”
Originally from Utah, Dr. Nadauld attended Brigham Young University for his undergraduate degree and went on to complete medical and doctoral degrees (MD/PhD) followed by internship and residency at the University of Utah. His doctoral dissertation focused on the molecular genetics of colon cancer. He completed a fellowship in medical oncology at Stanford University where he remained as faculty at the Stanford School of Medicine focusing on cancer genomics and personalized cancer medicine. Last year Dr. Nadauld was awarded the prestigious Young Investigator Award by the American Society of Clinical Oncology and the Career Development Award of the National Cancer Institute.
About Intermountain Precision Genomics
Intermountain Healthcare’s Precision Genomics’ mission is to extend the lives and quality of lives of Stage Four cancer patients. Through a unique approach, we provide the most advanced next generation sequencing (NGS) available. Our test, called ICG100, detects all possible gene mutation types, giving patients a 95% chance of targeted cancer therapy.
Precision Genomics is uniquely positioned to advance cancer genomics research because of their worldwide collaborative of scientists, physicians, and researchers dedicated to improving care. They also own and use the nation’s largest biorepository, which stores more than three million tissue samples used for the advancement of cancer research.
Dr. Nadauld presents recently published abstract at the American Association for Cancer Research conference